I am an applied social scientist specializing in health economics and health policy research.
Technological innovation is a major driver of continuing improvements in human health, but many promising health technologies struggle to make the move from bench to bedside in a timely manner.
My goal is to use health economics and outcomes research to help optimize the value propositions of new health technologies, and thereby facilitate their development, commercialization, and sustainable implementation.
As a Research Associate in the Collaboration for Outcomes Research and Evaluation (CORE) at UBC’s Faculty of Pharmaceutical Sciences, I have led and contributed to a wide range of health economics, health policy, and health services research projects. My work to date has focused primarily on genomic medicine and rare diseases, but current projects also include the use of early health technology assessment (eHTA) to inform medical product development and the use of natural language processing to facilitate research on patient experiences and preferences.
I am the Technical Lead for the Nanomedicines Innovation Network’s eHTA Platform, which aims to facilitate the commercialization of nanomedicine technologies developed by Canadian investigators. I am also a co-investigator and member of the health economics team for GenCOUNSEL, a large scale Genome Canada-funded project that is exploring strategies for ensuring adequate decision support and genetic counseling is available for patients and healthcare providers as genomic technologies become more integrated into routine healthcare delivery.
Prior to joining CORE as a CIHR– and MSFHR-funded postdoctoral fellow in 2013, I completed postdoctoral fellowships at the University of Calgary (2011-2013) and UBC’s Liu Institute for Global Issues (2010-2011). I hold a Ph.D. (2010) and M.A. (2004) in Political Science from the University of British Columbia, and a B.A. from Yale University (2003).
Areas of Expertise
Patient and Stakeholder Preferences
Health Technology Assessment